Edition:
United States

Mologen AG (MGNG.F)

MGNG.F on Frankfurt Stock Exchange

3.50EUR
11:14am EDT
Change (% chg)

€0.02 (+0.69%)
Prev Close
€3.48
Open
€3.53
Day's High
€3.54
Day's Low
€3.43
Volume
7,438
Avg. Vol
39,437
52-wk High
€4.99
52-wk Low
€1.15

Latest Key Developments (Source: Significant Developments)

Mologen Q1 EBIT loss widens to EUR 5.1 mln
Thursday, 11 May 2017 01:00am EDT 

May 11 (Reuters) - MOLOGEN AG ::SUCCESSFUL FINANCING AND CONTINUATION OF CLINICAL STUDIES WITH THE LEAD PRODUCT LEFITOLIMOD IN THE FIRST QUARTER 2017.FINANCIAL PERFORMANCE AND FINANCIAL POSITION OF MOLOGEN AG DEVELOPED ACCORDING TO PLAN IN Q1 OF 2017.DESPITE ONGOING ADVANCEMENT OF CLINICAL STUDIES, Q1 EXPENSES FOR RESEARCH AND DEVELOPMENT ONLY INCREASED SLIGHTLY YEAR ON YEAR TO EUR3.9 MILLION (Q1 2016: EUR3.7 MILLION.Q1 OPERATING RESULT (EBIT) WAS CONSEQUENTLY BELOW PREVIOUS YEAR TO EUR-5.1 MILLION (Q1 2016: EUR-4.5 MILLION).OUTLOOK FOR 2017 CONFIRMED.FUNDING SECURED UNTIL START OF 2018 THROUGH ADDITIONAL CAPITAL MEASURE.  Full Article

Mologen: new strategic orientation, funding secured until start of 2018 through capital measures
Wednesday, 22 Mar 2017 02:13am EDT 

Mologen AG : New strategic orientation, successful capital measures and notable study progress in 2016 . Confident forecast for 2017 . Funding secured until start of 2018 through capital measures . Lead product lefitolimod: significant milestones reached . On 31 March 2016, chief medical officer (CMO) Alfredo Zurlo left company . He is being succeeded by Matthias Baumann, who will start in his new position on 1 May 2017 .Funding secured until start of 2018 through capital measures secured future funding through two capital measures, with capital increase and convertible bond generating gross proceeds of 16.1 million euros ($17.39 million).  Full Article

Mologen announces combination data of EnanDIM with checkpoint inhibitor
Monday, 27 Feb 2017 04:01am EST 

Mologen AG : First combination data of TLR9 agonists EnanDIM with checkpoint inhibitor in preclinical tumor models .Preclinical in vivo data showed that EnanDIM can significantly improve anti-tumor effect of checkpoint inhibitor anti-PD-1, and thus prolong survival in a murine colon carcinoma tumor model.  Full Article

Mologen to launch convertible bond, aggregate value of up to EUR 4.99 mln
Thursday, 22 Dec 2016 12:54am EST 

Mologen AG : Said on Wednesday: public rights offering of a convertible bond with purchase guarantee by major shareholder amounting to 60 percent . Bonds are to be offered to existing shareholders by way of a prospectus-exempt public rights offering . Global Derivative Trading GmbH ("GDT"), the major shareholder of MOLOGEN AG, made a binding commitment to the company to purchase at least 299,999 partial bonds in total - representing around 60 percent of the convertible bond 2017/2025 . Issue volume: 4.99 million euros ($5.21 million), maturity of 8 years . Conversion price set at 1.60 euro; coupon of 6 percent p.a. .Expected subscription period: Dec. 28, 2016 to Jan. 13, 2017.  Full Article

Mologen to launch convertible bond, aggregate value of up to EUR 4.99 mln
Wednesday, 21 Dec 2016 02:33pm EST 

Mologen AG : Said on Wednesday: public rights offering of a convertible bond with purchase guarantee by major shareholder amounting to 60 percent . Bonds are to be offered to existing shareholders by way of a prospectus-exempt public rights offering . Global Derivative Trading GmbH ("GDT"), the major shareholder of MOLOGEN AG, made a binding commitment to the company to purchase at least 299,999 partial bonds in total - representing around 60 percent of the convertible bond 2017/2025 . Issue volume: 4.99 million euros ($5.21 million), maturity of 8 years . Conversion price set at 1.60 euro; coupon of 6 percent p.a. .Expected subscription period: Dec. 28, 2016 to Jan. 13, 2017.  Full Article

Mologen: capital increase through rights issue and issuance of convertible bond
Monday, 26 Sep 2016 01:52am EDT 

Mologen AG : Capital increase through rights issue and issuance of a convertible bond . Chinese investor commits to purchase up to 3.4 million new shares . Issue proceeds to be used for implementation of new "next level" strategy . Subscription price of 1.20 euros per new share .Issuing of up to 11,315,750 new shares.  Full Article

Mologen resolves capital increase
Friday, 23 Sep 2016 07:59am EDT 

Mologen AG : Resolves capital increase . Share capital to be increased from 22,631,501 euros by up to 11,315,750 euros ($12.69 million) to up to 33,947,251 euros by issuing of up to 11,315,750 new shares .Subscription price of 1.20 euros per new share.  Full Article

Mologen H1 EBIT loss widens to EUR 9.8 million
Thursday, 11 Aug 2016 01:23am EDT 

Mologen AG : Forecast for full year 2016 unchanged . H1 EBIT was below previous year's figure at -9.8 million euros (H1 2015: -6.9 million euros) . H1 expenses for research and development amounted to 7.1 million euros ($7.93 million)in total, which exceeded figure in previous year (H1 2015: 5.2 million euros) .As at June 30, 2016, available cash and cash equivalents amounted to 15.3 million euros (Dec. 31, 2015: 24.6 million euros).  Full Article

Mologen announces report of loss
Monday, 11 Jul 2016 10:52am EDT 

Mologen AG : Executive management board of Mologen indicates that company's provisional registered share capital is down to just 10,681,859.09 euros ($11.80 million)as of June 30, 2016 dated July 11, 2016 as a result of losses incurred . This means that half company's share capital of 22,631,501.00 euros has been wiped out by losses .Losses mostly result from company's ordinary activities as a research-based biotechnology company which is still developing and without revenues of its own.  Full Article

Mologen: medium-term funding from existing capital authorizations possible
Tuesday, 5 Jul 2016 10:15am EDT 

Mologen AG : Says medium-term funding from existing capital authorizations possible . Executive management board decided, with consent of supervisory board, not to propose resolution regarding capital measure to company's AGM on August 11, 2016 .Is currently planning to carry out a cash capital increase from authorized capital.  Full Article

BRIEF-Mologen: recruitment goal achieved for study with lefitolimod in colorectal cancer patients

* RECRUITMENT GOAL ACHIEVED FOR PIVOTAL IMPALA STUDY WITH LEFITOLIMOD IN COLORECTAL CANCER PATIENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)